The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
Abstract
BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage. METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin. Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. A total of 2377 serum samples (mean, 15.1 samples per patient) were obtained before, during, and after treatment with doxorubicin. Troponin T levels were evaluated in a blinded fashion to determine whether they were elevated (>0.01 ng per milliliter)--the primary end point--or extremely elevated (>0.025 ng per milliliter). RESULTS: Elevations of troponin T occurred in 35 percent of the patients (55 of 158). Patients treated with doxorubicin alone were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T levels (50 percent vs. 21 percent, P<0.001) and extremely elevated troponin T levels (32 percent vs. 10 percent, P<0.001). The median follow-up was 2.7 years. The rate of event-free survival at 2.5 years was 83 percent in both groups (P=0.87 by the log-rank test). CONCLUSIONS: Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin. Longer follow-up will be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years and on event-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Self-citationSilverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 865
Self-citationLipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Self-citationMertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3163 · Cited by 798
Morrow, D. A. (2001) · JAMA · doi:10.1001/jama.286.19.2405 · Cited by 656
Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Self-citationAnthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
Kremer, L. C. M., van Dalen, E. C., Offringa, M., Ottenkamp, J., & Voûte, P. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.191 · Cited by 399
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 384
Self-citationSpeyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Epidemiology of anthracycline cardiotoxicity in children and adults.
Ma, G., & Se, L. (1998) · PubMed · Cited by 341
Green, D. M., Grigoriev, Y. A., Nan, B., Takashima, J. R., Norkool, P. A., D’Angio, G. J., & Breslow, N. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1926 · Cited by 319
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.102 · Cited by 308
Self-citationSchuchter, L. M., Hensley, M. L., Meropol, N. J., & Winer, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.178 · Cited by 262
Möller, T. R., Garwicz, S., Barlow, L., Winther, J. F., Glattre, E., Olafsdottir, G., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3173 · Cited by 259
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D., Takeda, K., Yu, Z.-X., & Ferrans, V. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2237 · Cited by 210
Self-citationSilverman, L., Declerck, L., Gelber, R., Dalton, V., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Moghrabi, A., Samson, Y., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401980 · Cited by 166
Self-citationGianni, L., Zweier, J. L., Levy, A., & Myers, C. E. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88854-8 · Cited by 154
Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., YU, Z., Takeda, K., & Ferrans, V. J. (1998) · PubMed · Cited by 151
Self-citationChemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines
Hasinoff, B. B., Hellmann, K., Herman, E., & Ferrans, V. J. (1998) · Current Medicinal Chemistry · doi:10.2174/0929867305666220314194045 · Cited by 141
Green, D. M., Hyland, A. J., Chung, C. S., Zevon, M. A., & Hall, B. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3207 · Cited by 121
Herman, E. H., Zhang, J., Rifai, N., Lipshultz, S. E., Hasinoff, B. B., Chadwick, D. P., Knapton, A. D., Chai, J., & Ferrans, V. J. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100348 · Cited by 106
Self-citationVentricular dysfunction clinical research in infants, children and adolescents
Lipshultz, S. E. (2000) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(00)00076-x · Cited by 79
Self-citationSeymour, L., Bramwell, V., & Moran, L. A. (1999) · PubMed · Cited by 78
Collinson, P. O., & Stubbs, P. J. (2003) · Heart · doi:10.1136/heart.89.11.1285 · Cited by 68
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain, S. M. (1998) · PubMed · Cited by 51
Dexrazoxane (ICRF-187) Protects Cardiac Myocytes Against Hypoxia-Reoxygenation Damage
Hasinoff, B. B. (2002) · Cardiovascular Toxicology · doi:10.1385/ct:2:2:111 · Cited by 35
Schroeder, P. E., & Hasinoff, B. B. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0538-z · Cited by 33
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef, M. L., Synold, T. W., Chow, W. A., Leong, L., Margolin, K. A., Morgan, R. J., Raschko, J. W., Shibata, S., Somlo, G., Yen, Y., et al. (2001) · PubMed · Cited by 22
Ottlinger, M. E., Pearsall, L., Rifai, N., & Lipshultz, S. E. (1997) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(98)00004-6 · Cited by 20
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Metadata
- Authors
- Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-07-08
- Volume
- 351
- Issue
- 2
- Pages
- 145-153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2084196088
- Cited by
- 623
- References
- 34
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.